Published in Drug Law Weekly, May 12th, 2009
These data will be presented during one oral and two poster sessions at the annual meeting of the European Association for the Study of the Liver (EASL) being held this week in Copenhagen (April 22 – 26, 2009).
These new data, from a large, randomized, placebo-controlled study of 299 patients, showed that patients who received rifaximin (1100...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.